increasingli confid outlook reacceler revenu growth
least low doubl digit level base analysi popgen program
 ilmn clinic custom base includ detail analysi top custom
concurr analysi updat model increas price target
analysi popgen program quantifi revenu opportun
respect popgen program alway materi
plan schedul accordingli believ fair assum opportun
fulli translat actual revenu said keep mind believ
popgen revenu popgen materi growth driver
beyond addit detail pleas see page report
analyz outlook spend sequenc consum
top clinic custom clinic sequenc revenu forecast
revenu growth rest ilmn clinic sequenc custom group appli
believ fairli conserv assumpt combin led us conclud
clinic applic could gener increment revenu
addit detail pleas see page report
updat see financi forecast requir gener
increment revenu gener y/i growth model larg driven
sequenc consum note analysi suggest combin
popgen appli discount revenu opportun identifi clinic
applic gener increment revenu impli
sequenc consum revenu growth applic would need increas
y/i meet target framework boost convict ilmn abil re-
acceler total revenu growth least low double-digit level addit
detail pleas see page report
advanc expect earli januari updat take
opportun updat financi forecast roll quarterli annual
expect forecast total revenu growth slightli
consensu oper margin y/i increment ep
consensu ultim think good chanc
guid expect level
pleas see page report import disclosur
well posit maintain leadership expand high end genet
arm dealer elimin barrier sequenc becom increasingli use
clinic adjac market increasingli drive oper leverag bottom
 believ factor continu translat double-digit revenu
dcf support price target scenario assum moder revenu
growth next year translat ep
believ prove reason multipl next month clinic
consum and/or popseq program drive upsid build confid outlook
prolong mid-teen revenu growth believ share could trade higher bull
case next year
nextseq key growth driver
continu evolv favor
new instruments/kit surpris
sourc revenu
expand use sequenc increas
becom much favor
popgen program drive upsid
novaseq unabl catalyz
strength nextseq placement
concern build oper leverag
slow materi
hiseq bigger expect headwind
leader genet tool segment tool diagnost market segment
compani broad portfolio system consum analysi tool design
simplifi genet analysi address rang genom complex price point
throughput enabl research select best solut scientif challeng
market leader next gener sequenc increasingli focus popgen
initi act arm dealer emerg oncolog clinical/transl
analysi popgen program reveal potenti revenu opportun
respect popgen program
alway materi plan schedul accordingli believ fair assum
opportun fulli translat actual revenu said keep
mind believ popgen revenu popgen materi
growth driver beyond believ analysi boost
confid ilmn abil meet current financi target
identifi assess popul genet popgen program
mention and/or disclos sourc analysi base
best effort forecast potenti volum base disclos program target
util believ reason conserv price assumpt
whole genom sequenc
tough overal revenu growth moder y/i street
consensu current assum revenu growth reacceler
popgen expect key driver reacceler
popgen could account sequenc revenu base
assess
would prudent cautiou popgen program timelin oftentim slip
administr seemingli alway adequ anticip challeng
consent fund program announc beyond specif
would highlight given activ program
exampl depart abu dhabi announc decemb
patient genom project launch would use bgi oxford nanopor
platform rather technolog
current sell-sid consensu averag revenu forecast implicitli forecast
increas revenu y/i revenu growth y/i
believ popgen revenu confid build
gener increment revenu via popgen initi
believ seem plausibl base assess even acknowledg prior
disclaim would go long way least fortifi confid achiev
current revenu target
figur analysi select popul genet popgen program page
cowen compani compani report inform popgen program
program namecountrybackgroundfund detailsnumb ususath us research program seek creat one world largest comprehens precis medicin research platform data resourc contain multi-lay data particip feder fund author subject sequestr partner central florida divis healthcar provid advent health screen particip famili hypercholesterolemia fh studi call wholem helix use propreitari exom sequenc test cost advent fund council scientif industri research bcsir bangladeshlaunch januari program alreadi begun sequenc genom initi focu sequenc breast cancer patient program matur bcsir expect sequenc healthi volunt fund bangladesh governmentunclear target patient initi appear bangladesh aim sequenc patient in-countri versu send sampl genom projectchinalaunch decemb led research harbin institut technolog hit sequenc genom peopl across differ ethnic background region across china goal understand genet environment caus diseas initi fund fund china ministri scienc technologyfirst phase expect sequenc second phase third phase icin data centerchinaannounc octob part icin data nanj center program focu popul genet newborn childhood brain cognit develop cancer rare chronic diseas analyz genet databas studi genet mutat relat major cni ional genom centerdenmarkdenmark nation genom center name per center expect serv nation sequenc infrastructur manag nation genom databas make data avail research gov initi commit year begin gov also expect privat fund support program novo nordisk foundat announc expect invest dkk year start decemb sampl first year dubai genom initiativedubaith dubai author dha launch human genom popgen project part dubai initi februari project conduct least month uae nation target first resid potenti follow fund dubai govern author dubai initiativetot number resid dubai finngen research project base public-priv partnership finnish univers biobank hospit district sever intern pharmaceut compani drive research implement econom develop field person medicin studi expect continu six year secur fund gnomiqu french genom icin anticip franc capabl sequenc genom per year correspond patient rare diseas togeth famili high-prior patient metastat cancer cancer refractori treatment four pilot project cancer patient soft-tissu sarcoma colon cancer rare diseas common diseas sampl gener popul usath pennsylvania-bas system offer dna sequenc patient goal eventu extend offer geising patient absorb estim cost sequenc test per patient pilot began test look mutat least gene associ dozen medic condit rang heart diseas cancer well variabl peopl respond pharmaceut base canadacanada multi-phas project announc june focus rare diseas precis health phase expect sequenc patient rare diseas parent phase research expect sequenc larg nation popul cohort canadian unclear least site across canada provid access genom technolog fund canadian india projectindiaindia genom map initi sequenc individu sponsor depart biotechnolog data access via biobank depart biotechnolog fund project exact fund detail reveal sequenc analyz asain individu genom creat refer genom acceler asian specif medic advanc precis medicin genom nanyang tech univers found partner macrogen alreadi start process prior offici genomeasia process total cost geonm announc contribut supposedli biobank patient consent earli cowen
figur analysi select popul genet popgen program page
cowen compani compani report inform popgen program
program namecountrybackgroundfund detailsnumb medicin sweden swedenprimari focu sequenc patient select cancer hereditari diseas long term goal sequenc least patient per year receiv goal genotyp sampl per england ukgenom england launch genom fulli sequenc sanger institut award grant april evalu ove month goal sequenc sampl octob nh announc plan expand whole genom sequenc within award sanger run wg pilot expect lead sequenc entir sampl oct nh announc plan expand whole genom sequenc withinin next five year futur missionaustralia expect sequenc australiansaustralian govern expect invest part broader australian genom futur nevadausalaunch septemb hnp commun base popul health studi return clinic result studi volunt fundingprovid renownfound whole exom sequenc konghong konghong kong genom project hkgp aim sequenc patient genom dataset supplement sequenc data patient famili research cohort genom sequenc hong kong gov contribut per year year start patient case famili total total genom includ tumor/norm genom famili trio genom inherit precis genom programusain partnership decod studi collect dna sampl uniqu individu mostli utah provid detail inform genet earlier report alreadi award research commenc medicin ireland gmi acquir wuxi nextcod target volunt wg near term invest ireland strateg invest fund investor total mileston payment govern nation genom person medicin initi aim sequenc patient genom intent dvelop databas inform long-term diseas ill trend isra citizen sampl collect expect begin total fund isra begin collect mid mayb regeneronusamayo regeneron enet partnership sequenc individu collect we genotyp dataregeneron fund project million european genom allianceeumega eu initi particip countri start popgen effort unclear progress genom initiativeusath mgi collabor research effort among physician research univers michigan goal harmon patient electron medic record genet data gain novel biomed per veteran program mvp usamvp indic would like wg sampl wg complet wg contract award personali custom novemb septemb contract extend includ genom personali contract sequenc addit sampl genotyp interest wg medicin programme/ estonia biobankestoniain decemb institut genom announc first part mission collect dna sampl estonian accomplish day govern said alloc addit million help project continu aim give anoth peopl chanc give dna sampl data link nation health inform system decemb govern said alloc addit million help project unclear appear goal genotyp sampl genom programmeqatarqgp gener larg databas combin whole genom sequenc omic data comprehens phenotyp data collect qatar biobank support sidra medic research wg genom programsaudith saudi genom program shgp one nation transform program vision saudi arabia aim sequenc genom sampl identifi genet basi sever common genet diseas saudi popul fund king abdulaziz citi scienc technolog biobankukpilot phase vanguard project sequenc wg late uk biobank secur million pound sequenc remain wg compani like az gsk fund project access data share research government industri project goal sequenc vietnames individu compil analyz data databas access world-wide vietnames conglomer budget school medicineusath project head former director geising enrol patient per week patient per year goal project recruit particip potenti increas target number particip mostli connecticut yale school medicin yale new cowen
analyz outlook spend sequenc consum
top clinic custom forecast revenu growth rest ilmn clinic
sequenc custom group appli believ fairli conserv
assumpt combin led us conclud clinic applic could
gener increment sequenc consum revenu
believ assess boost confid ilmn abil least meet
seven compani cover cover among ilmn clinic
custom measur revenu base financi model maintain
compani knowledg compon compani cogs/test
abl assess histor project spend consum note
also includ best estim cover spend
tough overal revenu growth moder y/i street
consensu current assum revenu growth reacceler
head clinic applic account sequenc consum
revenu y/i build confid outlook robust clinic
sequenc revenu import context build confid
outlook meet beat current financi expect
estim compani spend consum
like account total
clinic sequenc revenu analysi suggest custom group spend
y/i sequenc consum
keep mind disclos clinic applic account total
sequenc consum revenu translat exclud
contribut compani note remain revenu
clinic custom assum clinic revenu increas per
year growth rate plausibl conserv could
would like gener revenu respect
group clinic custom exclud aforement compani
base understand custom applic think
reason growth assumpt clinic growth believ assess
reason even without meaning discount note like requir
recent popgen assess
analysi suggest clinic applic could drive increment
revenu meet current consensu revenu expect would need
gener increment revenu accordingli believ assess
help build confid ilmn abil least meet beat current
figur analysi clinic revenu opportun top clinic sequenc custom
cowen compani compani report
total total cogsperc total total total total total cog seem rightperc total gh believ total cog total fmi shift test ngspercent total base street revenu cog cowen
figur broader analysi outlook spend sequenc consum clinic custom
cowen compani compani report
growth materi step bring test in-hous growth move non- sequenc least growth reproduct believ cost other sequenc cog major lab growth growth total sequenc consum consum guidanc total high end sequenc consum clonoseq immunoseq dx volum growth includ va volum growth test asp growth growth cog fraction total cog consid piec growth equip use compani gross margin growth growth growth oncolog consum guidanc growth growth total sequenc consum total high end sequenc consum probabl twice high oncolog test growth clinic consum guidanc growth growth total sequenc consum total high end sequenc consum test process cogs/test due sequenc revenu cog test process cogs/test due sequenc revenu cog clinicalreproduct healthoncolog test process cogs/test due sequenc revenu cog cowen
cowen compani
select top clinic custom sequenc consum sequenc consum high end sequenc consum clinic custom sequenc consum clinic consum salesreproduct clinic consum high end sequenc consum due sequencingng test process revenu cog cowen
updat see financi forecast requir gener
increment revenu gener y/i growth model larg driven
sequenc consum analysi suggest combin popgen
appli discount revenu opportun identifi clinic
applic gener increment revenu impli
sequenc consum revenu growth applic would need increas
y/i meet target framework boost convict ilmn abil
re-acceler revenu growth least low double-digit level
advanc expect earli januari updat take
opportun updat financi forecast roll quarterli
forecast total revenu growth slightli
consensu oper margin y/i increment ep
consensu ultim think good chanc guid
expect level
assumpt forecast includ nomin instrument revenu growth
 sequenc consum revenu growth declin microarray
revenu sequenc servic revenu growth normal
dx access fee gel servic believ could prove conserv
keep mind model like sell side model believ driven
applic growth popgen clinic revenu forecast driven instrument
placement consum util assumpt current forecast
sequenc consum revenu growth via combin
expand instal base instrument number placement
 steadi consum util per instrument rel
model continu hiseq decreas modest novaseq increas
dollar term sequenc consum revenu need increas y/i
growth line forecast analysi includ report
suggest popgen clinic growth could gener
increment revenu mathemat impli sequenc consum
revenu applic research appli would need grow y/i
cowen compani compani report
consum cowen consum growth levelsperc total appli consum rebound growth y/i total research revenu cowen popgen contribut increment research growth revenu growth y/i research/appli excl popgen cowen
compani report cowen compani
yr cagrcomments/guidancetot revenu guid y/i reiter y/yrevenu product classproduct inst servic incl nextbio revenu geographyamerica statesothereurop middl east growth y/i revenu guid y/i reiter y/yproduct middl east revenu growth model reflect guidanc salesproduct middl east sequenc guid y/i reiter mid-teen servic consum growth revenu growth total revenu growth microarray guid y/i previous flat growth manag indic hope dtc stabil declin teen product revenu growth closer total revenu growth wors anticip apr expect mid-teen y/i comment purchas instrument lh array system strength partial function scale lhcowen comment manag indic largerli consum littl mainten believ largerli ancestri com cowen comment relat instrument maint contract remaind nipt popgen core ip/licens oncolog collabor also front ivd licens record note gel account servic revenu mostli cowen
compani report thomson eikon cowen compani
mm except per share guidancenet revenu guid y/i reiter y/yreport expect q/q margin slightli y/i gener oper expect increas revenu vs y/i sale opex non-oper interest q/qearn roughli flat q/qnet loss attribut nci add earn per ep vs roughli flat gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit greater-than-expect reduct academ
govern research fund competit commerci avail potenti
disrupt technolog price pressur caus competit increas demand
lower-pr instrument run-tim cost neg regulatori dynam
